Drug
Lestaurtinib clinical trials
Also written CEP-701.
- studies test it
- 10
- open now
- 0
- in phase 3
- 1
- first study started
- 2002
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 5
Cephalon (5) · Children's Oncology Group (2) · New Approaches to Neuroblastoma Therapy Consortium (1) · M.D. Anderson Cancer Center (1) · Ronald Hoffman (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lestaurtinib is read from its arms, and is right about nine times in ten.
Testing it · 10
- Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedPhase 3Children's Oncology GroupNCT00557193Written as Lestaurtinib
- N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk NeuroblastomaCompletedPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT00084422Written as lestaurtinib
- Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1/2Children's Oncology GroupNCT00469859Written as lestaurtinib
- Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential ThrombocytosisCompletedPhase 2CephalonNCT00586651Written as lestaurtinib
- CEP-701 (Lestaurtinib) in MyelofibrosisStatus unknownPhase 1/2Ronald HoffmanNCT00668421Written as CEP-701 (Lestaurtinib)
- Study of CEP-701 in Treatment of Prostate CancerCompletedPhase 2CephalonNCT00081601Written as CEP-701
- Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 MutationCompletedPhase 2CephalonNCT00030186Written as CEP-701 60mg
- Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe PsoriasisCompletedPhase 2CephalonNCT00236119Written as CEP-701 20mg
- Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple MyelomaTerminatedPhase 2CephalonNCT00242827Written as Oral CEP-701
- CEP-701 for PH-negative MyelofibrosisCompletedPhase 2M.D. Anderson Cancer CenterNCT00494585Written as CEP-701
Given in every arm · 1 — lestaurtinib is usual care beside what is tested
Codes
What other systems call lestaurtinib · ClinicalTrials.gg INT004156
- MeSH (NLM) C119379lestaurtinibOne source NLM
- UNII (FDA) DO989GC5D1LESTAURTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q6531771lestaurtinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48402LestaurtinibOne source FDA
- DrugBank DB06469One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C119379 | lestaurtinib | One source NLM |
| UNII (FDA) | DO989GC5D1 | LESTAURTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6531771 | lestaurtinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48402 | Lestaurtinib | One source FDA |
| DrugBank | DB06469 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.